Till­man Gern­gross is bet­ting well over $500M that the pan­dem­ic will nev­er re­al­ly end. Here’s the IPO pitch

Tillman Gerngross doesn’t waffle. The longtime Dartmouth professor and Adimab founder tends to pick a course and drive straight for the goal. If he sees a big, ugly nail, he’ll start to design a …
( read original story …)

---